Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a new pill keep multiple myeloma in check after transplant?

NCT ID NCT04564703

Ongoing Disease control Sponsor: Stichting European Myeloma Network Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the drug iberdomide (CC220) as a long-term maintenance therapy for people with newly diagnosed multiple myeloma who have already had a stem cell transplant. The goal is to see if taking iberdomide continuously can improve the depth of response and help keep the cancer from coming back. The study enrolls about 160 participants and will also monitor side effects and how well people tolerate the treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
iberdomide (CC220), a drug taken continuously as maintenance therapy after autologous stem cell transplant
What this could lead to
If successful, this could lead to a new maintenance option that improves response rates and delays relapse in multiple myeloma patients after transplant.
What could go wrong
This is a phase 2 trial with a moderate number of participants, so results may not confirm long-term benefit or safety. The drug may cause side effects leading to dose reductions or discontinuation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

  • A.O. S. Maria

    Terni, Italy

  • A.O. Spedali Civili di Brescia

    Brescia, Italy

  • A.O.U. Careggi

    Florence, Italy

  • A.O.U. Città della Salute e della Scienza di Torino-Ematologia U

    Torino, Italy

  • A.O.U. Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi di Ancona

    Ancona, Italy

  • A.O.U. Policlinico S. Martino - Ematologia

    Genova, Italy

  • A.O.U. di Bologna - Policlinico S. Orsola Malpighi

    Bologna, Italy

  • Albert Schweitzer Hospital

    Dordrecht, Netherlands

  • Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens

    Athens, Greece

  • Breda-Amphia Ziekenhuizen

    Breda, Netherlands

  • C.H.U. Strasbourg

    Strasbourg, France

  • CHU Hôtel-Dieu

    Nantes, France

  • CHU Hôtel-Dieu, 1, place Alexis Ricordeau, 44093 NANTES Cedex 1, FRANCE

    Nantes, France

  • Centre Hospitalier Universitaire de Bordeaux

    Bordeau, France

  • Centre Hospitalier Universitaire de Dijon

    Dijon, France

  • Erasmus University Medical Center

    Rotterdam, Netherlands

  • Institut Universitaire Du Cancer De Toulose

    Toulouse, France

  • Ospedale Generale Regionale-Divisione di Ematologia e Centro Trapianto Midollo Osseo

    Bolzano, Italy

  • Policlinico S. Matteo Fondazione IRCCS

    Pavia, Italy

  • Saint Antoine Hospital, Hematology Department

    Paris, France

  • Theagenio Cancer Hospital

    Thessaloniki, Greece

  • Vrije Universiteit Medical Center (VUMC)

    Amsterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.